FTC: ‘Pharma bro’ Shkreli violated lifetime industry ban, should be held in contempt — Live Feedhttps://www.live-feeds.com/feed/ftc-pharma-bro-shkreli-violated-lifetime-industry-ban-should-be-held-in-contemptContinuously updated, source-cited coverage. FTC and States Seek Contempt Ruling Against Martin Shkrelihttps://www.live-feeds.com/feed/ftc-pharma-bro-shkreli-violated-lifetime-industry-ban-should-be-held-in-contempthttps://www.live-feeds.com/feed/ftc-pharma-bro-shkreli-violated-lifetime-industry-ban-should-be-held-in-contempt#u135866Mon, 19 Oct 2026 12:45:31 +0000The Federal Trade Commission and seven states are asking a federal court to hold Martin Shkreli in contempt for allegedly violating a lifetime ban from the pharmaceutical industry. Authorities claim Shkreli has repeatedly and flagrantly ignored the 2022 court order by participating in the sector, trading stocks, and sinking share prices for small biotechnology companies. Shkreli was originally barred from the industry following a trial that found he organized an illegal monopoly scheme for the drug Daraprim. State and federal regulators now want the court to penalize him for breaching these le